Probiodrug AG has secured €15 million from venture capitalists and private investors to support its programme for glutaminyl cyclase inhibitors, the lead compound of which is set to move towards clinical proof of concept in Alzheimer’s disease.
Probiodrug AG has secured €15 million from venture capitalists and private investors to support its programme for glutaminyl cyclase inhibitors, the lead compound of which is set to move towards clinical proof of concept in Alzheimer’s disease.